202 related articles for article (PubMed ID: 36528604)
1. Serum metabolic traits reveal therapeutic toxicities and responses of neoadjuvant chemoradiotherapy in patients with rectal cancer.
Wang H; Jia H; Gao Y; Zhang H; Fan J; Zhang L; Ren F; Yin Y; Cai Y; Zhu J; Zhu ZJ
Nat Commun; 2022 Dec; 13(1):7802. PubMed ID: 36528604
[TBL] [Abstract][Full Text] [Related]
2. Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer.
Jia H; Shen X; Guan Y; Xu M; Tu J; Mo M; Xie L; Yuan J; Zhang Z; Cai S; Zhu J; Zhu Z
Radiother Oncol; 2018 Sep; 128(3):548-556. PubMed ID: 30041962
[TBL] [Abstract][Full Text] [Related]
3. Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer.
Jacobs L; van der Vlies E; Ten Bokkel Huinink D; Bloemendal H; Intven M; Smits AB; Weusten BLAM; Siersema PD; van Lelyveld N; Los M
Clin Colorectal Cancer; 2018 Sep; 17(3):179-186. PubMed ID: 29661620
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
5. The Gut Microbiome Is Associated With Therapeutic Responses and Toxicities of Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients-A Pilot Study.
Shi W; Shen L; Zou W; Wang J; Yang J; Wang Y; Liu B; Xie L; Zhu J; Zhang Z
Front Cell Infect Microbiol; 2020; 10():562463. PubMed ID: 33363048
[TBL] [Abstract][Full Text] [Related]
6. Changes of serum metabolites levels during neoadjuvant chemoradiation and prediction of the pathological response in locally advanced rectal cancer.
Lv J; Jia H; Mo M; Yuan J; Wu Z; Zhang S; Zhe F; Gu B; Fan B; Li C; Zhang T; Zhu J
Metabolomics; 2022 Nov; 18(12):99. PubMed ID: 36441416
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
[TBL] [Abstract][Full Text] [Related]
8. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer.
Serna G; Ruiz-Pace F; Hernando J; Alonso L; Fasani R; Landolfi S; Comas R; Jimenez J; Elez E; Bullman S; Tabernero J; Capdevila J; Dienstmann R; Nuciforo P
Ann Oncol; 2020 Oct; 31(10):1366-1375. PubMed ID: 32569727
[TBL] [Abstract][Full Text] [Related]
9. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
[TBL] [Abstract][Full Text] [Related]
10. A deep neural network predictor to predict the sensitivity of neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Liu Y; Shi J; Liu W; Tang Y; Shu X; Wang R; Chen Y; Shi X; Jin J; Li D
Cancer Lett; 2024 May; 589():216641. PubMed ID: 38232812
[TBL] [Abstract][Full Text] [Related]
11. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
12. ceRNA Networks: The Backbone Role in Neoadjuvant Chemoradiotherapy Resistance/Sensitivity of Locally Advanced Rectal Cancer.
He L; Chang H; Qi Y; Zhang B; Shao Q
Technol Cancer Res Treat; 2021; 20():15330338211062313. PubMed ID: 34908512
[TBL] [Abstract][Full Text] [Related]
13. Relations of Changes in Serum Carcinoembryonic Antigen Levels before and after Neoadjuvant Chemoradiotherapy and after Surgery to Histologic Response and Outcomes in Patients with Locally Advanced Rectal Cancer.
Saito G; Sadahiro S; Ogimi T; Miyakita H; Okada K; Tanaka A; Suzuki T
Oncology; 2018; 94(3):167-175. PubMed ID: 29268274
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of carcinoembryonic antigen combined with carbohydrate antigen 19-9 following neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
Zheng Z; Wang X; Lu X; Huang Y; Chi P
Colorectal Dis; 2021 Sep; 23(9):2320-2330. PubMed ID: 33900006
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the tumor microenvironment and identification of spatially predictive biomarkers associated with beneficial neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Zhang S; Li N; Wang F; Liu H; Zhang Y; Xiao J; Qiu W; Zhang C; Fan X; Qiu M; Li M; Tang H; Fan S; Wang J; Luo H; Li X; Lin J; Huang Y; Liang L
Pharmacol Res; 2023 Nov; 197():106974. PubMed ID: 37898442
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of changes in the level of carbohydrate antigen 19-9 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Zheng Z; Wang X; Huang Y; Lu X; Chi P
Colorectal Dis; 2020 Dec; 22(12):2068-2077. PubMed ID: 32936987
[TBL] [Abstract][Full Text] [Related]
17. Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy.
Ji D; Yi H; Zhang D; Zhan T; Li Z; Li M; Jia J; Qiao M; Xia J; Zhai Z; Song C; Gu J
Cancer Immunol Res; 2018 Nov; 6(11):1401-1416. PubMed ID: 30282671
[TBL] [Abstract][Full Text] [Related]
18. [Advances in the prediction of the efficacy and sensitivity of neoadjuvant chemoradiotherapy in rectal cancer].
Ji Q; Li YF; Wu T
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):392-397. PubMed ID: 31054555
[TBL] [Abstract][Full Text] [Related]
19. Response prediction of neoadjuvant chemoradiation therapy in locally advanced rectal cancer using CT-based fractal dimension analysis.
Tochigi T; Kamran SC; Parakh A; Noda Y; Ganeshan B; Blaszkowsky LS; Ryan DP; Allen JN; Berger DL; Wo JY; Hong TS; Kambadakone A
Eur Radiol; 2022 Apr; 32(4):2426-2436. PubMed ID: 34643781
[TBL] [Abstract][Full Text] [Related]
20. Rectal Cancer Tissue Lipidome Differs According to Response to Neoadjuvant Therapy.
Sánchez-Vinces S; Duarte GHB; Messias MCF; Gatinoni CFA; Silva AAR; Sanches PHG; Martinez CAR; Porcari AM; Carvalho PO
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
